403 Correlative analysis of blood and biopsy samples from a clinical trial of Hsp90 inhibition in combination with pembrolizumab reveals increased intratumoral myeloid cell accumulation after treatment

Benzer Materyaller

• 403 Correlative analysis of blood and biopsy samples from a clinical trial of Hsp90 inhibition in combination with pembrolizumab reveals increased intratumoral myeloid cell accumulation after treatment
  Yazar:: Mohammad Zaidi, ve diğerleri
  Baskı/Yayın Bilgisi: (2021-11-01)
• XL888 and pembrolizumab modulate the immune landscape of colorectal tumors in a phase Ib/II clinical trial
  Yazar:: Maggie J. Phillips, ve diğerleri
  Baskı/Yayın Bilgisi: (2025-12-01)
• 904 Repurposing CD26 (DPP4) inhibitors to enhance immunotherapy response in pancreatic ductal adenocarcinoma
  Yazar:: Thomas Mace, ve diğerleri
  Baskı/Yayın Bilgisi: (2021-11-01)
• Moving Immunoprevention Beyond Virally Mediated Malignancies: Do We Need to Link It to Early Detection?
  Yazar:: Madhav V. Dhodapkar, ve diğerleri
  Baskı/Yayın Bilgisi: (2019-10-01)
• High-content, high-throughput analysis of cell cycle perturbations induced by the HSP90 inhibitor XL888.
  Yazar:: Susan K Lyman, ve diğerleri
  Baskı/Yayın Bilgisi: (2011-03-01)